Jonathan Strober, MD

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

Jonathan Strober, MD, discusses advancements in pediatric myasthenia gravis, emphasizing the need for better treatment standards and effective patient care strategies.

Jonathan Strober, MD, discusses the challenges of diagnosing pediatric myasthenia gravis, especially in seronegative cases, and the importance of antibody testing.

Nipocalimab shows promise in treating myasthenia gravis in children, with ongoing trials revealing safety and efficacy similar to adult studies, says Jonathan Strober, MD.

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 Vibrance-MG study investigator, he explains the difficulty of evaluating investigative treatments for pediatric patients who have myasthenia gravis.

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

"The newer medications that are coming out, and a lot of them are approved, are much more focused on the problem," explains Jonathan Strober, MD, pediatric neurologist with UCSF Benioff Children's Hospital.